Palvella Therapeutics, Inc.

Palvella reported approximately $251 million in cash at June 30, 2026. Management said 2026 cash spend is now expected to be approximately $85 million to $95 million, modestly higher due to launch-readiness investments. No revenue, EPS or gross margin figures were given on this call. Forward-looking targets remained unchanged: NDA submission in the second half of 2026 and potential FDA approval in the first half of 2027 for QTORIN rapamycin in microcystic lymphatic malformations. For cutaneous venous malformations, management said it expects FDA approval in the 2029 timeframe, with Phase III initiation still targeted for the fourth quarter; DSAP Phase II is expected to start in the second half of 2026; angiokeratoma data are expected in the second half of 2027.

Wes Kaupinen framed the quarter as a major de-risking period, highlighting the FDA pre-NDA meeting, rolling review, and first NDA module submission as key milestones. He emphasized Palvella’s “pipeline-in-a-product” strategy, saying the company is building toward multiple first-in-disease therapies across rare skin diseases and vascular malformations. His tone was confident and launch-oriented, with repeated emphasis on urgency, discipline and capital efficiency.

Matt Korenberg highlighted the strengthened balance sheet, saying cash was approximately $251 million at quarter-end, supported by the February financing that raised $230 million versus an original $150 million target. He said the company is expanding commercial and medical investments, including a larger planned field force and earlier medical science liaison hiring, and that these changes lift expected 2026 cash spend to $85 million to $95 million. He added that Palvella still expects to enter launch with more capital than originally expected.

Analysts focused on market sizing, launch execution and regulatory path. Management said its conservative estimate remains greater than 30,000 diagnosed microcystic lymphatic malformation patients in the U.S., with claims work previously suggesting 45,000 to 95,000 diagnosed patients and about 1,500 or more annual new diagnoses. On cVM, management said it will meet FDA for an End of Phase II discussion, did not think lack of Breakthrough Designation changes the path forward, and believes a strong data package plus patient interview transcripts could support future resubmission. Questions also covered pricing, prior auth and possible step-throughs; management said it does not expect unapproved therapy step-throughs based on payer research and sees prior auth as manageable with a dedicated access team.